Sağlık Taramalarında Danışmanlık Nasıl Yapılmalıdır?

Periyodik Sağlık Muayenesi (PSM), sağlıklı görünen kişilerin yaş, cinsiyet ve risk faktörlerine görebelirlenen sıklıkta değerlendirilmesidir. Bu değerlendirmenin önemli bir bileşeni de tarama testleridir.Uygulanacak tarama testi kişiler tarafından kabul edilebilir olmalıdır. Hekimlerin önerilen PSM ile ilgiliyarar/zarar oranı hususunda, görüşmeci model prensipleri doğrultusunda hastaları bilgilendirmesiönemlidir.

How Should Counseling Be Done in Health Screenings?

Periodic Health Evaluation (PHE) is the assessment at a frequency that is shaped according to the age, gender, and risk factors of healthy‐looking people. An important component of this assessment is screening tests. The screening test to be performed should be acceptable to persons. It is important for physicians to inform patients about the benefit / damage ratio related to the suggested PHE by the principles of interviewer model.

PDF

___

1. Mazıcıoğlu M, Uzuner A. Aile Doktorları için Kurs Notları, 1.Aşama. Ankara: TC.Sağlık Bakanlığı; 2004:99‐109.
2. Kligman EW, Hale FA. Family Medicine: Principles and Practice. Taylor RB, ed. Family Medicine, Principles and Practice. 5th ed. New York: Springer‐Verlag; 1997:29‐52.
3. United States Preventive Services Task Force (USPSTF): Guide to Clinical Preventive Services, U.S. Department of Health and Human Services Agency for Healthcare Research and Quality. 2019; https://www.uspreventiveservicestaskforce.org/Page/Name/uspstf‐a‐and‐b‐ recommendations/. Erişim Tarihi: 03.03.2019.
4. Birtwhistle R, Bell N, Thombs B, Grad R, Dickinson J. Periodic preventive health visits: a more appropriate approach to delivering preventive services. Canadian Family Physician. 2017;63(11):824‐6.
5. Canadian Task Force on Preventive Health Care. https://canadiantaskforce.ca/guidelines/published‐guidelines/. Erişim Tarihi: 03.03.2019.
6. Summary of Recommendations for Clinical Preventive Services. 2017; https://www.aafp.org/dam/AAFP/documents/patient_care/clinical_recommendations/cps‐ recommendations.pdf. Erişim Tarihi: 05.03.2019.
7. Viera A, Power D. Koruma ve Taramaya Genel Bakış. Sloane PD, ed. (Palandüz A.çev.) Aile Hekimliğinin Esasları. 6. ed. İstanbul: Medikal Sağlık ve Yayıncılık; 2015:29‐35.
8. Warner EA, Herold AH. Interpreting Laboratory Tests. Rakel RE, ed. Textbook of Family Practice. Philadelphia: Elsevier Saunders; 2016:157‐80.
9. Galen RS, Gambino SR. Beyond normality: The Predictive Value and Efficacy of Medical Diagnosis. New York: John Wiley & Sons; 1975:171‐5.
10. Duane M, Mishori R. Sağlam Erişkin Bakımı. Sloane PD, ed. (Palandüz A.çev.) Aile Hekimliğinin Esasları. 6. ed. İstanbul: Medikal Sağlık ve Yayıncılık; 2015:61‐75.
11. Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727‐37, W237‐42.
12. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine. 2009;151(10):738‐47.
13. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, DL M. Cumulative probability of false‐positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155(8):481‐92.
14. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost‐ effectiveness. Ann Intern Med. 2011;155(1):10‐20.
15. van Ravesteyn NT, Miglioretti DL, Stout NK, et al. What level of risk tips the balance of benefits and harms to favor screening mammography starting at age 40? Ann Intern Med. 2012;156(9):609‐17.
16. Grossman DC, Curry SJ, Owens DK, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901‐13.
17. Hamrick IM. Reports From the AAFP FMX Conference: Top 10 Updates in EBM. https://www.practiceupdate.com/content/reports‐from‐the‐aafp‐fmx‐conference‐top‐10‐ updates‐in‐ebm/75261/62. Erişim Tarihi: 10.03.2019.
18. Campos‐Outcalt D. Preventive Health Care. Rakel RE, ed. Textbook of Family Medicine. 9th ed.: Elsevier; 2016:85‐7.
19. Lalkhen AG, McCluskey A. Clinical tests: sensitivity and specificity. Continuing Education in Anaesthesia Critical Care & Pain. 2008;8(6):221‐3.
20. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317:307‐12.
21. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;156(7):491‐9.
22. Kopans DB. The positive predictive value of mammography. AJR Am J Roentgenol. 1992;158(3):521‐6.
23. Grimes DA, Schulz KF. Uses and abuses of screening tests. The Lancet. 2002;359(9309):881‐4.
24. Wegwarth O, Schwartz LM, Woloshin S, Gaissmaier W, Gigerenzer G. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med. 2012;156(5):340‐9.
25. Guideline on Impaired Vision. Canadian Task Force on Preventive Health Care;2018.
https://canadiantaskforce.ca/guidelines/published‐guidelines/impaired‐vision/. Erişim Tarihi: 10.03.2019.
26. Altınel M, Akçakaya MA. Yaşlılık ve Göz. Okmeydanı Tıp Dergisi. 2013;29(2):110‐5.
27. Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti‐cancer Randomized Trial (J‐START): a randomised controlled trial. The Lancet. 2016;387(10016):341‐8.
28. Starting M. Mammography screening for breast cancer. N Engl J Med. 2012;367:31.
29. Aile Hekimliği Uygulamasında Önerilen Periyodik Muayeneleri ve Tarama Testleri Rehberi. Ankara: T.C. Sağlık Bakanlığı Aile Hekimliği Eğitim ve Geliştirme D. Başkanlığı;2015. https://www.pediatridunyasi.org/common/getCommonFile.aspx?document=200026. Erişim Tarihi: 10.03.2019.